Company: DVAX
Filing Date: 2025-04-21
Form Type: DEFC14A
Source: 0001193125-25-087127
Chunk: 12

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-21
Form: DEFC14A
Chunk 12
---
) incumbent directors of the Company (including one director who was recently appointed by the Board). If elected, the Deep Track Nominees will represent a minority of the members of the Board, and
therefore, may be unable to implement any actions that may be necessary to enhance stockholder value. However, we believe that the election of the Deep Track Nominees is an important step in the right direction for enhancing long-term value at the
Company. You should refer to the Company’s proxy statement for the names, background, qualifications and other information concerning the Company’s nominees.

This Proxy Statement is soliciting proxies to elect the four Deep Track Nominees. We have provided the required notice to the Company pursuant
to the universal proxy rules, including Rule 14a-19(a)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and we intend to solicit the holders of Common Stock representing
at least 67% of the voting power of Common Stock entitled to vote on the election of directors in support of director nominees other than the Company’s nominees.

THE DEEP TRACK NOMINEES

The following
description sets forth the name, age, present principal occupation, and employment and material occupations, positions, offices or employments for the past five (5) years of the Deep Track Nominees. This information has been furnished to us by
the Deep Track Nominees. The nomination was made in a timely manner and in compliance with the applicable provisions of the Company’s governing instruments. The specific experience, qualifications, attributes and skills that led us to conclude
that the Deep Track Nominees should serve as directors of the Company are also set forth below.

Brett Erkman, age 44.

Since October 2022, Brett Erkman has served as a Managing Director of Deep Track Capital, an investment firm focused on the life sciences.
Prior to Deep Track Capital, he was a biotechnology investor at Great Point Partners from October 2006 through April 2022. Previously, Mr. Erkman was a sell side associate at ThinkEquity Partners and a financial analyst at Abbott Laboratories.
Mr. Erkman holds a B.S. in Finance from DePaul University.

Mr. Erkman has been analyzing investments in biotechnology companies for
20 years. As such, he would bring many skills to his service on the Board of directors including financial acumen, strategic thinking, an understanding of risk management, and insight into the health care markets